EGFR and non-small cell lung carcinoma: All patients with NSCLC eventually develop resistance to antitumor agents, including endothelial growth factor receptor (EGFR) inhibitors and chemotherapeutics, possibly due to abnormal signal transduction and EGFR overexpression [5–7].